Final Results for 13 months to 31 December 2019
RNS & Investor News
SlimBiome® wins award at Vitafoods 2018
18 May 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces that it has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva. The award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market.
SlimBiome® is a next generation patented weight management ingredient developed by world leading key opinion leaders in nutrition and satiation to help manage weight loss by reducing hunger. This leads to less snacking and easier weight loss. It is heat stable, easy to process and has been incorporated into bread, biscuits, dairy, gummies, muesli pots, healthy snacks & bars, and a range of cereals in puff, flakes, and crisp format.
Independent human studies by Oxford Brookes University have demonstrated that if you compare control and test groups who take SlimBiome® or a placebo, the SlimBiome® group: -
- Feel fuller and are less hungry
- Have less food cravings
- Change their food choice so eat less sweet or fatty foods
This contrasts with current products on the market which often lack strong scientific evidence or clinical studies and typically rely on customers' self-control to restrict calories and as a consequence have a high failure rate. Independent consumer studies have shown that 100% of customers who used SlimBiome® in OptiBiotix's GoFigure® products lost weight, on average 2-3lbs per week. Most importantly these customers found the products relieve hunger pangs leading to easier dieting.
The award for Weight Management Ingredient of the Year at Vitafoods is the second industry award for SlimBiome®, following on from winning the award for 'Best Functional Ingredient for Health and Well Being' at Food Matters in November 2017.
SlimBiome® is the first in a range of products being developed by OptiBiotix which help to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome®, CardioBiome® and WellBiome®.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to receive this award which provides independent industry recognition of the innovation and scientific credibility behind the development of SlimBiome® and it's potential to help manage weight gain and improve consumers health and wellbeing. Having a product with a known mechanism of action, clinical and consumer studies showing its safety and effectiveness, and the support of leading international key opinion leaders, helps give confidence to consumers in their product choice. Hunger free dieting is now a consumer option and we hope that the increasing number of food applications containing SlimBiome® will help bring the benefits of this exciting new technology to a wider international audience."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP||Tel: 020 7213 0880|
|Liam Murray / Jo Turner|
|finnCap (Broker)||Tel: 020 7220 0500|
|Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020